Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 9
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
9| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 8383659 | XDEMVYlotilaner | substance, product | Jan 2030 |
| 10835517 | XDEMVYlotilaner | use | Dec 2038 |
| 11197847 | XDEMVYlotilaner | use | Dec 2038 |
| 11690826 | XDEMVYlotilaner | use | Dec 2038 |
| 11690827 | XDEMVYlotilaner | use | Dec 2038 |
| 11752137 | XDEMVYlotilaner | product | Dec 2038 |
| 12171750 | XDEMVYlotilaner | use | Dec 2038 |
| 12213964 | XDEMVYlotilaner | product | Dec 2038 |
| 12364685 | XDEMVYlotilaner | product | Dec 2038 |
| Product | Exclusivity | Until |
|---|---|---|
| XDEMVYLOTILANER | NCE New chemical entity | Jul 2028 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| XDEMVY | Lotilaner ophthalmic solution | solution/ drops, ophthalmic | 81942-125NDA |
Enquiry
Common questions
- Is Tarsus Pharmaceuticals, Inc. FDA approved?
- Tarsus Pharmaceuticals, Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Tarsus Pharmaceuticals, Inc. make?
- 1 product is listed under Tarsus Pharmaceuticals, Inc. in the openFDA NDC Directory, most often as solution/ drops. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.